2023 Update: AMH levels can now be used as an alternative to ultrasound for the diagnosis of Polycystic Ovarian Morphology (PCOM) in adults.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Evaluation of reproductive-age patients with irregular menses (oligomenorrhea or amenorrhea).
Workup for signs of hyperandrogenism (hirsutism, acne, androgenetic alopecia).
Infertility evaluation related to anovulation.
Differentiating PCOS from other endocrine disorders (e.g., NCCAH, Cushing’s, thyroid dysfunction).
Diagnosis Requirements
Diagnosis of PCOS requires the presence of at least 2 out of the 3 Rotterdam criteria, provided other etiologies (CAH, androgen-secreting tumors, Cushing’s) have been excluded.
Section 2
Formula & Logic
The Three Pillars
Oligo- and/or Anovulation: Menses at intervals >35 days or <9 per year.
Polycystic Ovaries (on Ultrasound): ≥12 follicles (2–9 mm) in either ovary and/or increased ovarian volume (>10 mL).
Updated Ultrasound Thresholds (2018/2023)
With modern high-frequency transducers (≥8 MHz), the follicle count per ovary (FNPO) threshold for PCO morphology is now ≥20 follicles in either ovary.
Exclusionary Workup
TSH
Rule out Thyroid Dysfunction
Prolactin
Rule out Hyperprolactinemia
17-OHP
Rule out Non-classic CAH
Total Testosterone
Rule out Androgen-secreting tumors (if >150 ng/dL)
Section 3
Pearls/Pitfalls
Phenotypic Variation
The Rotterdam criteria allow for four distinct PCOS phenotypes: Phenotype A (Full: Hyperandrogenism + Ovulatory dysfunction + PCO), B (Non-PCO), C (Ovulatory), and D (Non-hyperandrogenic). Phenotypes A and B carry the highest risk for metabolic syndrome and insulin resistance.
Adolescent Diagnostic Caveats
In adolescents (<8 years post-menarche), BOTH hyperandrogenism and ovulatory dysfunction must be present. Ultrasound morphology is unreliable in this age group as multicystic ovaries are a common physiological finding during puberty.
Clinical Pearls
Clinical hirsutism is a more reliable marker of hyperandrogenism than biochemical testing in many patients.
Anti-Müllerian Hormone (AMH) is often elevated in PCOS but is not yet formally part of the Rotterdam diagnostic criteria.
Polycystic ovaries (PCO) alone do NOT constitute PCOS; approximately 20% of normo-ovulatory women have PCO morphology.
Section 4
Next Steps
Management Pathways
01
Assess for metabolic comorbidities: 2-hour OGTT (preferred over HbA1c) and fasting lipid panel.
02
Lifestyle Modification: First-line for all BMI categories to improve ovulatory function and metabolic profile.
03
Cycle Regulation: Combined Oral Contraceptive Pills (COCPs) are first-line to prevent endometrial hyperplasia.
04
Hyperandrogenism: COCPs +/- Spironolactone (wait 6 months for effect; ensure contraception as it is teratogenic).
05
Infertility: Letrozole is now first-line for ovulation induction (superior to Clomiphene in PCOS).
Related Tools
Ferriman-Gallwey Hirsutism Score
HOMA-IR Calculator
Endometrial Cancer Risk Assessment
Section 5
Evidence Appraisal
Foundational Consensus
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group • Fertility and Sterility. 2004;Established the current diagnostic framework by expanding on the 1990 NIH criteria to include PCO morphology.
Modern Guidelines
Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
Teede HJ et al. • Fertility and Sterility. 2023;The current global standard for PCOS management, reinforcing the Rotterdam criteria while updating ultrasound and AMH considerations.
Section 6
Literature
The Shift in Definition
Prior to 2003, the NIH criteria (1990) required both hyperandrogenism and oligo-ovulation. The Rotterdam meeting, held in the Netherlands, recognized that excluding PCO morphology missed a large cohort of women with similar metabolic and reproductive risks, leading to the current broader definition.
Global Collaboration
The criteria represent a rare consensus between the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM), aiming to standardize PCOS research and clinical care worldwide.
